Колоректальный рак у больных пожилого возраста: обзор литературы

В связи с глобальным демографическим старением колоректальный рак все чаще диагностируется у пациентов пожилого и старческого возраста, что создает серьезную медико-социальную проблему. Дефицит данных из-за недостаточного включения этой группы в клинические исследования приводит к вариабельности лечебных подходов. Целью данного обзора является систематизация современных знаний для формирования персонализированной стратегии ведения таких пациентов. Ключевыми аспектами являются специфические особенности колоректального рака у пожилых, обязательное применение комплексной гериатрической оценки для стратификации рисков и индивидуализации лечения, а также адаптация хирургических и лекарственных методов с учетом возрастных изменений фармакологии и профиля безопасности. Наиболее эффективной признана модель, интегрирующая принципы гериатрии и онкологии, которая позволяет оптимизировать соотношение пользы и риска, улучшая результаты лечения и качество жизни пациентов.

1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. https://doi.org/10.3322/caac.21660.

2. Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019;69(5):363–385. https://doi.org/10.3322/caac.21565.

3. Ludmir EB, Mainwaring W, Lin TA, et al. Factors associated with age disparities among cancer clinical trial participants. JAMA Oncol. 2019;5(12):1769–1773. https://doi.org/10.1001/jamaoncol.2019.2055.

4. Chen TC, Liang JT, Chang TC. Should surgical treatment Be provided to patients with colorectal cancer who are aged 90 Years or older? J Gastrointest Surg. 2018;22(11):1958–1967. https://doi.org/10.1007/s11605-018-3843-5.

5. Hurria A, Dale W, Mooney M, et al. Designing therapeutic clinical trials for older and frail adults with cancer: U13 conference recommendations. J Clin Oncol. 2014;32(24):2587–2594. https://doi.org/10.1200/JCO.2013.55.0418.

6. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. https://doi.org/10.3322/caac.21708.

7. Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol. 2007;25(14):1824–1831. https://doi.org/10.1200/JCO.2007.10.6559.

8. Meguid RA, Slidell MB, Wolfgang CL, et al. Is there a difference in survival between right-versus left-sided colon cancers? Ann Surg Oncol. 2008;15(9):2388–2394. https://doi.org/10.1245/s10434-008-0015-y.

9. Weiss JM, Pfau PR, O'Connor ES, et al. Mortality by stage for rightversus left-sided colon cancer: analysis of surveillance, epidemiology, and end results-Medicare data. J Clin Oncol. 2011;29(33):4401–4409. https://doi.org/10.1200/JCO.2011.36.4414.

10. Carethers JM. One colon lumen but two cancers. Gastroenterology. 2011;141(4):1146–1150. https://doi.org/10.1053/j.gastro.2011.06.029.

11. Venderbosch S, Nagtegaal ID, Maughan TS, et al. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res. 2014;20(20):5322–5330. https://doi.org/10.1158/1078-0432.CCR-14-0332.

12. Yamauchi M, Morikawa T, Kuchiba A, et al. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut. 2012;61(6):847–854. https://doi.org/10.1136/gutjnl-2011-300865.

13. Iacopetta B. Are there two sides to colorectal cancer? Int J Cancer. 2002;101(5):403–408. https://doi.org/10.1002/ijc.10635.

14. Loupakis F, Yang D, Yau L, et al. Primary tumor location as a prognostic factor in metastatic colorectal cancer. J Natl Cancer Inst. 2015;107(3):dju427. https://doi.org/10.1093/jnci/dju427.

15. Gefen R, Emile SH, Garoufalia Z, et al. Characteristics and role of surgery in nonagenarians with colorectal cancer: SEER database analysis. Surgery. 2025;181:109161. https://doi.org/10.1016/j.surg.2025.109161.

16. Papamichael D, Audisio RA, Glimelius B, et al. Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013. Ann Oncol. 2015;26(3):463–476. https://doi.org/10.1093/annonc/mdu253.

17. Kumar A, Sahoo B, Jaiswal A, et al. Delayed presentation of colorectal cancer: a continuing challenge. Cureus. 2021;13(10):e18439.

18. O'Connell JB, Maggard MA, Liu JH, et al. Do young colon cancer patients have worse outcomes? World J Surg. 2004;28(6):558–562. https://doi.org/10.1007/s00268-004-7306-7.

19. Hurria A, Dale W, Mooney M, et al. Designing therapeutic clinical trials for older and frail adults with cancer: U13 conference recommendations. J Clin Oncol. 2014;32(24):2587–2594. https://doi.org/10.1200/JCO.2013.55.0418.

20. Hugen N, Brown G, Glynne-Jones R, et al. Advances in the care of patients with mucinous colorectal cancer. Nat Rev Clin Oncol. 2016;13(6):361–369. https://doi.org/10.1038/nrclinonc.2015.140.

21. Chen TC, Liang JT, Chang TC. Should surgical treatment Be provided to patients with colorectal cancer who are aged 90 Years or older? J Gastrointest Surg. 2018;22(11):1958–1967. https://doi.org/10.1007/s11605-018-3843-5.

22. Sung JJY, Lau JYW, Young GP, et al. Asia Pacific consensus recommendations for colorectal cancer screening. Gut. 2008;57(8):1166–1176. https://doi.org/10.1136/gut.2007.146316.

23. Tie J, Cohen JD, Wang Y, et al. Circulating tumor DNA analyses as markers of recurrence risk and benefit of adjuvant therapy for stage III colon cancer. JAMA Oncol. 2019;5(12):1710–1717. https://doi.org/10.1001/jamaoncol.2019.3616.

24. Rex DK, Boland CR, Dominitz JA, et al. Colorectal cancer screening: recommendations for physicians and patients from the U.S. Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2017;153(1):307–323. https://doi.org/10.1053/j.gastro.2017.05.013.

25. Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386–1422. https://doi.org/10.1093/annonc/mdw235.

26. Extermann M, Aapro M, Bernabei R, et al. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol. 2005;55(3):241–252. https://doi.org/10.1016/j.critrevonc.2005.06.003.

27. Dekker E, Tanis PJ, Vleugels JLA, et al. Colorectal cancer. Lancet. 2019;394(10207):1467–1480. https://doi.org/10.1016/S0140-6736(19)32319-0.

28. Extermann M, Aapro M, Bernabei R, et al. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol. 2005;55(3):241–252. https://doi.org/10.1016/j.critrevonc.2005.06.003.

29. Wildiers H, Heeren P, Puts M, et al. International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol. 2014;32(24):2595–2603. https://doi.org/10.1200/JCO.2013.54.8347.

30. Kenig J, Zychiewicz B, Olszewska U, et al. The impact of frailty on outcome after radical surgery for colorectal cancer: a systematic review. Colorectal Dis. 2020;22(10):1242–1252.

31. Zhang X, Wang Y, Zhao L, et al. Nutritional status and shortterm outcome of patients undergoing colorectal cancer surgery. Nutr Cancer. 2021;73(5):850–857.

32. Aparicio T, Jouve JL, Teillet L, et al. Geriatric factors predict chemotherapy feasibility: ancillary results of FFCD 2001-02 phase III study in first-line chemotherapy for metastatic colorectal cancer in elderly patients. J Clin Oncol. 2013;31(11):1464–1470. https://doi.org/10.1200/JCO.2012.42.9894.

33. Mohile SG, Dale W, Somerfield MR, et al. Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology. J Clin Oncol. 2018;36(22):2326–2347. https://doi.org/10.1200/JCO.2018.78.8687.

34. Decoster L, Van Puyvelde K, Mohile S, et al. Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations. Ann Oncol. 2015;26(2):288–300. https://doi.org/10.1093/annonc/mdu210.

35. Bellera CA, Rainfray M, Mathoulin-Pélissier S, et al. Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. Ann Oncol. 2012;23(8):2166–2172. https://doi.org/10.1093/annonc/mdr587.

36. Soubeyran P, Bellera C, Goyard J, et al. Validation of a screening test for elderly patients in oncology. J Clin Oncol. 2008;26(15_suppl):20568.

37. Ommundsen N, Wyller TB, Nesbakken A, et al. Preoperative geriatric assessment and tailored interventions in frail older patients with colorectal cancer: a randomized controlled trial. Colorectal Dis. 2018;20(1):16–25. https://doi.org/10.1111/codi.13785.

38. Papamichael D, Audisio RA, Glimelius B, et al. Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013. Ann Oncol. 2015;26(3):463–476. https://doi.org/10.1093/annonc/mdu253.

39. Gefen R, Sameh HE, Garoufalia Z, et al. Characteristics and role of surgery in nonagenarians with colorectal cancer: SEER database analysis. Surgery. 2025;181:109161. https://doi.org/10.1016/j.surg.2025.109161.

40. Zeng W, Liu M, Zhou Z, et al. Outcomes of colorectal cancer surgery in nonagenarian patients: a multicenter retrospective study. J Gastrointest Oncol. 2021;12(4):1568–1576. https://doi.org/10.21037/jgo-21-324.

41. Abu-Helalah MA, Alshraideh HA, Da'na M, Al-Hanaqtah M, Abuseif A, Arqoob K, Ajaj A. Delay in Presentation, Diagnosis and Treatment for Colorectal Cancer Patients in Jordan. J Gastrointest Cancer. 2016 Mar;47(1):36-46. https://doi.org/10.1007/s12029-015-9783-3.

42. Lakatta EG. Age-associated cardiovascular changes in health: impact on cardiovascular disease in older persons. Heart Fail Rev. 2002;7(1):29–49. https://doi.org/10.1023/a:1013797722156.

43. Kaye KS et al. The Effect of Surgical Site Infection on Older Operative Patients. https://doi.org/10.1111/j.1532-5415.2008.02053.x

44. Bakker IS, Grossmann I, Henneman D, et al. Risk factors for anastomotic leakage and leak-related mortality after colonic cancer surgery in a nationwide audit. Br J Surg. 2014;101(4):424–432. https://doi.org/10.1002/bjs.9395.

45. White RH et al. Incidence of venous thromboembolism in the elderly: a population-based study. J Thromb Haemost. 2006;4(3):467–471.

46. Robinson TN, Wu DS, Stiegmann GV, Moss M. Frailty predicts increased hospital and six-month healthcare cost following colorectal surgery in older adults. Am J Surg. 2011;202(5):511–514. https://doi.org/10.1016/j.amjsurg.2011.06.017.

47. Veldkamp R, Kuhry E, Hop WCJ, et al. Laparoscopic surgery versus open surgery for colon cancer: short-term outcomes of a randomised trial. Lancet Oncol. 2005;6(7):477–484. https://doi.org/10.1016/S1470-2045(05)70221-7.

48. Guillou PJ, Quirke P, Thorpe H, et al. Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial). Lancet. 2005;365(9472):1718–1726. https://doi.org/10.1016/S0140-6736(05)66545-2.

49. Extermann M, Aapro M, Bernabei R, et al. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol. 2005;55(3):241–252. https://doi.org/10.1016/j.critrevonc.2005.06.003.

50. Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57(1):6–14. https://doi.org/10.1046/j.1365-2125.2003.02007.x.

51. McLean AJ, Le Couteur DG. Aging biology and geriatric clinical pharmacology. Pharmacol Rev. 2004;56(2):163–84. https://doi.org/10.1124/pr.56.2.4.

52. Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev. 2009;41(2):67–76. https://doi.org/10.1080/03602530902722679.

53. Wynne HA, Cope LH, Mutch E, et al. The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology. 1989;9(2):297–301. https://doi.org/10.1002/hep.1840090222.

54. Schmucker DL. Liver function and phase I drug metabolism in the elderly: a paradox. Drugs Aging. 2001;18(11):837–851. https://doi.org/10.2165/00002512-200118110-00005.

55. Innocenti F, et al. Age-specific functional polymorphisms of UGT1A1 influence pharmacokinetics and toxicity of irinotecan in pediatric and adult cancer patients. Cancer Res. 2006.

56. van der Bol JM, Mathijssen RHJ, Creemers G-JM, et al. A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan. Clin Cancer Res. 2010;16(2):736–742. https://doi.org/10.1158/1078-0432.CCR-09-1526.

57. Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc. 1985;33(4):278–285. https://doi.org/10.1111/j.1532-5415.1985.tb07117.x.

58. Swedko PJ, Clark HD, Paramsothy K, et al. Serum creatinine is an inadequate screening test for renal failure in elderly patients. Arch Intern Med. 2003;163(3):356–360. https://doi.org/10.1001/archinte.163.3.356.

59. Stevens LA, Coresh J, Greene T, et al. Assessing kidney function--measured and estimated glomerular filtration rate. N Engl J Med. 2006 ;354(23):2473–2483. https://doi.org/10.1056/NEJMra054415.

60. Balducci L., et al. Patient management strategies for older cancer patients: cognition and communication. J Natl Compr Canc Netw. 2005.

61. Extermann M, Overcash J, Lyman GH, et al. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol. 1998;16(4):1582–1587. https://doi.org/10.1200/JCO.1998.16.4.1582.

62. Argyriou AA, Kyritsis AP, Makatsoris T, Kalofonos HP. Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature. Cancer Manag Res. 2014;6:135–147. https://doi.org/10.2147/CMAR.S44261.

63. Kosmas C, Kallistratos MS, Kopterides P, et al. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol. 2008;134(1):75–82. https://doi.org/10.1007/s00432-007-0250-9.

64. van Kuilenburg AB, Muller EW, Haasjes J, et al. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency. Clin Cancer Res. 2001;7(5):1149–1153.

65. Slaviero K.A., et al. Population pharmacokinetics of irinotecan and its metabolites in patients with metastatic colorectal cancer. Cancer Chemother Pharmacol. 2003.

66. André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350(23):2343–2351. https://doi.org/10.1056/NEJMoa032709.

67. Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol. 2011;29(25):3457–3465. https://doi.org/10.1200/JCO.2011.34.7625.

68. Bellera CA, Rainfray M, Mathoulin-Pélissier S, et al. Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. Ann Oncol. 2012;23(8):2166–2172. https://doi.org/10.1093/annonc/mdr587.

69. Grothey A, Sobrero AF, Shields AF, et al. Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. N Engl J Med. 2018;378(13):1177–1188. https://doi.org/10.1056/NEJMoa1713709.

70. Shi Q, Ou FS, Lenz HJ, et al. Prospective pooled analysis of elderly patients (pts) with colon cancer (CC) enrolled in six phase III trials: How many are fit for oxaliplatin (Ox)? J Clin Oncol. 2018;36(15_suppl):3510.

71. Aparicio T, Lavau-Denes S, Phelip JM, et al. Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02). Ann Oncol. 2016;27(1):121–127. https://doi.org/10.1093/annonc/mdv491.

72. Cremolini C, Schirripa M, Antoniotti C, et al. First-line chemotherapy for mCRC – a review and evidence-based algorithm. Nat Rev Clin Oncol. 2015;12(10):607–619. https://doi.org/10.1038/nrclinonc.2015.129.

73. Lacouture ME, Maitland ML, Segaert S, et al. A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer. 2010;18(4):509–522. https://doi.org/10.1007/s00520-009-0744-x.

74. Grothey A, Sugrue MM, Purdie DM, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol. 2008;26(33):5326–5334. https://doi.org/10.1200/JCO.2008.16.3212.

75. Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–2520. https://doi.org/10.1056/NEJMoa1500596.

76. Lyman GH, Kuderer NM, Crawford J, et al. Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer. 2011;117(9):1917–1927. https://doi.org/10.1002/cncr.25691.

77. Benson AB 3rd, Ajani JA, Catalano RB, et al. Recommended guidelines for the treatment of cancer treatmentinduced diarrhea. J Clin Oncol. 2004;22(14):2918–2926. https://doi.org/10.1200/JCO.2004.04.132.